STUDY NAME |
DZ SITE |
STUDY Description |
ARMS |
# PTS |
A011801 |
HER2 + Breast Can be either ER/PR + or - |
The COMPASSHER2 Trials (Comprehensive use of Pathologic Response ASSessment to Optimize Therapy In HER2 Postive Breast Cancer): COMPASSHER2 Residual Disease (RD); A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib Must have completed at least 6 cycles of chemotherapy preoperatively or postoperatively |
ARM 1- T-DMM1 and placebo x 14 cycles
ARM 1 – T-DM1 and tucatinib x 14 cycles |
|
ALCHEMIST A151216 |
Non-Squamous Lung |
A Screening Trial for AO81105, and E4512 Observational Trial for Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell (Non-Squamous) Lung Cancer that has been or will be removed by Surgery” No neoadjuvant chemo or RT. No locally advanced or met cancer |
Pre-Register give 3 blood specimens btw post-surgery to 30 days post registration. Step 1 FFPE Block Collected. If EGFR confirmed enroll in A081105.. If ALK+ enroll in E4512 |
1 |
ALCHEMIST A081801 |
NSCLC |
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST-IO Must have EGRF, ALK, PD-LI IHC local testing with no identified arrangements. Must have completely resected dz IB (>/= 4cm), II or IIIA NSCLC with negative margins Patients with N2 Disease completely resected are eligible. However, patients with known N2 dz prior to surgery or ineligible. |
Initial Therapy: Arm A: 4 Cycles of Platinum doublet With Observation afterwards. Arm B: 4 Cycles of Platinum doublet with 17 cycles of Keytruda Amr C: 4 Cycles of Platinum doublet + Keytruda with 13 more cycles of Keytruda. |
0 |
AstraZeneca D4191C00140 |
Biliary Tract Cancers |
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE) |
Durvalumab 1500 mg plus gemcitabine-based chemotherapy |
|
EA5182
|
NSCLC |
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab vs. AZD9291 (Osimertinib) Alone as First Line Treatment for Patients with Metastatic EGRR-Mutant Non Small Cell Lung Cancer (NSCLC) |
Arm A: Osimertinib 80 mg po daily Amr B: Osimertinib 80 mg po daily + Bevacizumab 15 mg kg IV every 3 weeks |
|
S2302 |
NSCLC |
A Prospective Randomized Study of Ramucirumab + Pemrbolizumab vs. standard of care for participants previously treated with Immnotherapy for Stage IV or recurrent NSCLC |
Arm A: Investigator’s SOC Arm B: Ramucirumab + Pembrolizumab |
|
NRG-GI008 Study provides Natera Kits free of charge to the patient
|
Stage III CRC
|
Colon Adjuvant Chemotherapy based on Evaluation of Residucal Disease (Circulate-US) Cohort B – ctDNA positive Arm 3 – mFOLFOX 6 or CAPOX for 6 months A4m 4 – mFOLFIRINOX for 6 months |
Cohort A ctDNA-neg |
|
MorphoSys |
Diffuse Large B Cell Lymphoma |
Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second or third line therapy and not receiving autologous stem cell transplant |
|
|